Publications by authors named "L Paruzzo"
Article Synopsis
- Many patients treated with FDA-approved CAR T cells see their disease progress, especially with solid cancers and certain types of blood cancers like T cell lymphomas.
- A major challenge in adoptive T cell therapies is the dysfunction of CAR T cells, which struggle to expand and last after being infused.
- The study reveals that knocking out the CD5 gene using CRISPR-Cas9 can improve the antitumor abilities of CAR T cells by enhancing their function and persistence, suggesting CD5 as a key target for improving T cell therapies.
Article Synopsis
- Acute myeloid leukemia (AML) remains difficult to treat despite new therapies, highlighting the need for effective immune responses against the disease.
- The review emphasizes various immunotherapy targets, including both cancer cell features and the surrounding environment, and suggests personalized treatment strategies.
- Key immunotherapy methods discussed include immune checkpoint inhibitors, antibody-drug conjugates, therapeutic vaccines, and CAR-T/NK cells, while also addressing resistance mechanisms and the impact of the leukemia microenvironment on treatment outcomes.
Article Synopsis
- - The study identifies the interaction between BTLA on T cells and HVEM on regulatory T cells as a major factor limiting the effectiveness of T cell-based immunotherapies in tumors.
- - High levels of BTLA in CAR T cells are linked to poorer treatment outcomes, prompting researchers to delete BTLA to improve the T cells' tumor-fighting abilities.
- - By removing BTLA, T cells show enhanced signaling and function, suggesting that targeting the BTLA-HVEM interaction could boost the success of CAR T cell therapies.
Article Synopsis
- The study explores access to CART19 immunotherapy for large B-cell lymphomas among minority health populations (MHPs) compared to non-MHPs in different hospital settings.
- It found that while MHPs had access to care for LBCL, their representation in CART19 therapy was lower, with only 6.7% at the Abramson Cancer Center and 4.2% at the Knight Cancer Institute receiving the treatment.
- Outcomes for MHPs who did receive CART19 were similar to non-MHPs regarding response and survival, but the small sample size necessitates further research to confirm these findings.
Chimeric antigen receptor (CAR) T cell therapy targeting CD19 elicits remarkable clinical efficacy in B-cell malignancies, but many patients relapse due to failed expansion and/or progressive loss of CAR-T cells. We recently reported a strategy to potently restimulate CAR-T cells in vivo, enhancing their functionality by administration of a vaccine-like stimulus comprised of surrogate peptide ligands for a CAR linked to a lymph node-targeting amphiphilic PEG-lipid (termed CAR-T-vax). Here, we demonstrate a general strategy to generate and optimize peptide mimotopes enabling CAR-T-vax generation for any CAR.
View Article and Find Full Text PDF